key: cord-1015705-7isba0e7
authors: Cheng, Alexandre Pellan; Cheng, Matthew Pellan; Gu, Wei; Lenz, Joan Sesing; Hsu, Elaine; Schurr, Erwin; Bourque, Guillaume; Bourgey, Mathieu; Ritz, Jerome; Marty, Francisco M.; Chiu, Charles Y.; Vinh, Donald Cuong; De Vlaminck, Iwijn
title: Cell-Free DNA Tissues-of-Origin by Methylation Profiling Reveals Significant Cell, Tissue and Organ-Specific injury related to COVID-19 Severity
date: 2021-01-16
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.01.001
sha: e485e780d3a55da935e3251243c2edba7c188ed5
doc_id: 1015705
cord_uid: 7isba0e7

Background COVID-19 primarily affects the lungs, but evidence of systemic disease with multi-organ involvement is emerging. Here, we developed a blood test to broadly quantify cell, tissue, and organ specific injury due to COVID-19. Methods Our test leverages genome-wide methylation profiling of circulating cell-free DNA in plasma. We assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 plasma samples from 33 COVID-19 patients and compared to samples from patients with other viral infections and healthy controls. Findings We found evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. The concentration of cell-free DNA correlated with the WHO ordinal scale for disease progression and was significantly increased in patients requiring intubation. Conclusion This study points to the utility of cell-free DNA as an analyte to monitor and study COVID-19.

COVID-19 primarily affects the lungs, but evidence of systemic disease with multi-organ 30 involvement is emerging. Here, we developed a blood test to broadly quantify cell, tissue, and 31 organ specific injury due to COVID-19. 32 33 Methods 34

Our test leverages genome-wide methylation profiling of circulating cell-free DNA in plasma. We 35 assessed the utility of this test to identify subjects with severe disease in two independent, 36 longitudinal cohorts of hospitalized patients. Cell-free DNA profiling was performed on 104 37 plasma samples from 33 COVID-19 patients and compared to samples from patients with other 38 viral infections and healthy controls. 39 40 Findings 41 We found evidence of injury to the lung and liver and involvement of red blood cell progenitors 42 associated with severe COVID-19. The concentration of cell-free DNA correlated with the WHO 43 ordinal scale for disease progression and was significantly increased in patients requiring 44 intubation. 45 46 Conclusion 47 This study points to the utility of cell-free DNA as an analyte to monitor and study COVID-19. 48 49

Funding 50

The Coronavirus Disease-19 pandemic is a major global health crisis. COVID-19 is 60 a complex disease with diverse clinical features, ranging from asymptomatic infection to acute 61 respiratory distress syndrome (ARDS) and multi-organ dysfunction. There is an urgent need for 62 predictive biomarkers of COVID-19 severity detectable early in disease onset, and improved 63 understanding of the pathogenesis of COVID-19. Here, we have investigated the utility of 64 circulating cell-free DNA (cfDNA) in blood as an analyte i) to broadly monitor cell, tissue, and 65

organ injury due to COVID-19, ii) to assess disease severity and predict disease outcomes, and 66

iii) to elucidate the multi-organ involvement that characterizes COVID- 19. 67 Autopsy studies indicate a broad organotropism for the SARS-CoV-2 virus beyond the lungs 1,2 . 68 Detection of the virus in the kidneys, heart, liver, brain and blood of many patients has been 69 reported 2, 3 . The significant viral burden in the kidney seen in some patients may help explain 70 the increased risk of acute kidney injury in patients with COVID-19. Damage to endothelial cells 71 may contribute to COVID-19 coagulopathy and prothrombic state [4] [5] [6] [7] [8] . 72

Initial reports have primarily described COVID-19 as a disease affecting tissues expressing 73 ACE-2 9 . However, there are emerging data that SARS-CoV-2 infection may also be 74 accompanied by hematological derangements [10] [11] [12] [13] . In addition, a dysregulated immune 75 response to SARS-CoV-2 can occur, contributing to the development of ARDS, systemic tissue 76 injury, and multi-organ failure 14 . A strong association between increased cytokine profiles and 77 the severe deterioration of some patients has been observed 15 . In children, a multisystem 78 inflammatory syndrome linked to recent SARS-CoV-2 infection is reported 16 . Given the 79 disparate clinical manifestations and potential complications of COVID-19, there is an urgent 80 need for tests that can quantify injury to multiple tissues simultaneously to monitor patients, 81

analyze disease pathogenesis, predict clinical outcomes, and guide clinical management in 82 patients with Since the advent of cfDNA-based noninvasive prenatal testing, myriad applications of cfDNA in 84 diagnostic medicine have been established [17] [18] [19] . These short fragments of circulating DNA are 85 the debris of dead cells from across the body. The value of cfDNA as a quantitative marker of 86 tissue and organ injury was first recognized in solid-organ transplantation, where the level of 87 transplant donor derived cfDNA in the blood is now widely used as a marker of transplant 88 rejection [20] [21] [22] . More recently, several approaches have been developed to quantify the tissues-89 of-origin of cfDNA and thus monitor injury to any cell, tissue or organ type [23] [24] [25] [26] [27] . This is achieved 90 by profiling epigenetic marks within cfDNA by quantitative molecular measurement technologies 91 such as DNA sequencing. Here, we tested the hypothesis that cfDNA tissues-of-origin profiling 92 enables the identification of specific tissue or cell types that are directly or indirectly targeted 93 and injured throughout COVID-19 pathogenesis. We studied two independent patient cohorts, 94

and found evidence of significant injury to the liver, lung, and kidney associated with COVID-19. 95 We further observed a striking increase, both in terms of proportion and total abundance, of 96 cfDNA derived from red blood cell precursors when compared to patients infected with other 97 RNA viruses and healthy controls. Last, the total burden of cfDNA correlated with the WHO 98 ordinal scale for disease progression, with an increase in cfDNA being strongly associated with 99 admission to the intensive care unit and need for mechanical ventilation. Thus, cfDNA can 100 provide a marker of disease severity as well as a prognostic tool that is straightforward to adopt. We tested the utility of cfDNA to quantify cell, tissue, and organ specific injury associated with 105 COVID-19 in two independent patient cohorts from two different hospitals in North America ( Fig.  106 1A, patient characteristics in supplementary table 1,2). We assayed a total of 104 plasma 107 samples from 33 patients across these cohorts. We performed shotgun DNA sequencing after 108 bisulfite treatment to determine the tissues-of-origin of cfDNA isolated from all plasma samples 109 by methylation profiling. We obtained 62 ± 35 million (mean ± standard deviation) paired-end 110 reads per sample, leading to a per-base genome coverage of 1.3 ± 0.8. We verified that we 111 achieved a high bisulfite conversion efficiency for all samples (0.996 ± 0.005, Methods). To 112 determine the cell, tissue, and organ types that contribute cfDNA to the mixture in blood 113

(Methods), we analyzed plasma cfDNA methylation profiles against a reference set of 147 cell, 114

tissue, and organ types using previously described bioinformatic approaches (Fig. 1B and Respiratory syncytial virus B (n=1) (Fig. 2B) . 133

We plotted the relative abundance of cfDNA derived from different cell, tissue, and organ types 134 and found that differences in cfDNA profiles between individuals were larger than differences 135 within individuals over the sampling period. For subjects Z1, Z5, Z6, and Z42 but not Z12, we 136 observed gradual changes in the tissues-of-origin profiles over sampling periods of six to seven 137 days. We used the Bray Curtis dissimilarity to quantify the inter and intra-individual differences 138 in cfDNA profiles ( Fig. 2C-D) . This analysis confirmed the visual appearance of the tissues-of-139 origin profiles in Figure 2A and demonstrated that the largest differences in cfDNA were found 140 for samples collected from different individuals. Within subjects, smaller differences were 141 observed for samples collected on the same day (Fig. 2D) . Last, the Bray Curtis dissimilarity 142 increased with time interval between samples for patients Z1, Z5, Z6, and Z42 but not for Z12. 143 We verified that these observations were not affected by differences in the plasma volume of 144 different samples (supplementary figure 1A) . Together these analyses indicate that cfDNA 145 profiles are subject specific, and that changes in cfDNA tissues-or-origin profiles occur gradually 146 over days and not hours, therefore adequate longitudinal data can be collected every few days. 147

We next compared the cfDNA tissues-of-origin profiles associated with COVID-19 versus those 148 associated with respiratory infection with other viruses (Fig. 2E, supplementary table 3) . We 149 J o u r n a l P r e -p r o o f 5 found significant increases in the relative proportion of lung specific cfDNA in the blood of 150 COVID-19 patients, which was likely related to COVID-19 associated tissue injury (2.5% vs 151 0.6%, p-value = 0.019, Wilcoxon). We found a similar association with liver-derived cfDNA 152 (5.0% vs 0.9%, p-value = 0.025, Wilcoxon), and this was validated by the elevated liver function 153 tests in 4 of 5 COVID-19 patients. Strikingly, we also observed an increase in the relative 154

proportion of cfDNA derived from erythroblasts in the blood of COVID-19 patients compared to 155 the control group (75% vs 17% samples with an erythroblast fraction greater than 0, p-value = 156 0.003, 2-sample proportions test, Fig. 2E, supplementary figure 1B) . Erythroblasts are 157 nucleated cells typically in the adult bone marrow from which red blood cells develop and have 158 been shown to contribute circulating cfDNA to plasma 28 . The increase in cfDNA derived from 159 red blood progenitor cells seen here may be an indirect consequence of the hypoxemia and/or 160 cytokine-mediated anemia that characterize severe COVID-19, or may indicate a more direct 161 involvement of coronavirus with red blood cell precursors. We note that erythroblast cfDNA was 162 elevated in a single patient in the control group, who was being treated for recurrent stage IV 163 diffuse large B-cell lymphoma ( Fig. 2 B,E) . 164

To test the robustness of these initial observations, we assayed an additional 52 samples 166 collected from 28 after treatment and six patients died. Serial samples were collected from these patients at three 175 predetermined time points: days 1, 5, and 15 after enrollment in the clinical trial, provided they 176 remained hospitalized on the days of collection (Fig. 3A) . We determined the relative 177 abundance of tissue-specific cfDNA using the approaches described above. In addition, we 178 quantified the absolute concentration of tissue-specific cfDNA by multiplying the proportion of 179 tissue-specific cfDNA with the concentration of total cfDNA (Methods). 180

We first compared the cfDNA tissues-of-origin profiles measured for these patients with the 181 tissues-of-origin profiles for four healthy subjects ( was associated with decreased survival probability (p-value = 0.0052, log-rank test, high and 201 low defined as greater or equal to 6% erythroblast-derived cfDNA or less than 6%, respectively, 202

Kaplan-Meier supplementary figure 2D-G). 203

We next compared cfDNA signatures for COVID-19 patients as function of disease severity, and 204

found that erythroblast cfDNA proportions at any timepoint are predictive of in-hospital mortality 205 ( We then compared the cfDNA tissues-of-origin profiles to the 10-point WHO clinical status 213

ordinal scale for COVID-19 29 (Fig. 3C) . We found a strong association between the total cfDNA 214 concentrations isolated from plasma and the WHO clinical progression scores (Fig. 3C,D) . 215 Notably, a clinical score of 7 or greater (indicating the need for admission to the intensive care 216 unit and invasive mechanical ventilation), was associated with a sharp increase in the total 217 burden of cfDNA (Fig. 3C,D tend to bleed and require additional blood volumes, which may contribute to the increased 226 erythroblast signal. However, erythroblast-derived cfDNA was significantly increased in patients 227

with a clinical score of 7 or higher as well (Fig. 3C strong predictor of COVID-19 outcome 30, 31 . LDH is found in virtually all cells and is a commonly 243 used biomarker for tissue damage and hemolysis [32] [33] [34] . We found significant correlation between 244 7 LDH and the proportion of erythroblast-derived cfDNA (R = 0.64, ρ = 0.65), and between LDH 245 and total cfDNA (R = 0.67, ρ = 0.76). Together, these data suggest that cfDNA tissues-of-origin 246

can be applied to resolve the specific tissues contributing to non-specific detection of LDH in 247 blood. To evaluate whether cfDNA offers diagnostic value beyond conventional protein 248 biomarkers (ALT, AST, CRP, total bilirubin, LDH, RDWCV, hematocrit, hemoglobin, creatinine), 249

we developed a composite machine learning ensemble method (Extra Trees method 35 ) 250

incorporating all biochemical markers, the proportions of erythroblast, kidney, liver, lung and 251 neutrophil cfDNA, and total cfDNA concentration (Methods). Feature importance analysis 252

identified erythroblast and kidney-derived cfDNA as the most informative for COVID-19 mortality 253 prediction by this model (supplementary figure 3A,B) . ROC analysis with cross-validation 254

indicated that the composite model using cfDNA outperforms a model that only used 255 conventional biomarkers (AUC 0.91 vs. 0.73, respectively, supplementary figure 3A,B) . 256

We found no differences between lung, liver, kidney or erythroblast-derived cfDNA for patients 257 receiving standard of care, or the experimental lopinavir/ritonavir treatment (supplementary 258 figure 3C ). These data are in line with the results of recent clinical trials that treatment with 259 lopinavir/ritonavir is not significantly different from standard of care treatment for COVID-19 36, 37 . 260

Finally, we tested the prognostic value of biophysical properties of cfDNA and the burden of 261 mitochondrial cfDNA since these factors have previously been shown to have diagnostic value 262 in other disease settings 24, [38] [39] [40] [41] . We investigated the distribution of cfDNA fragment lengths 263

represented in the sample (mean, median), fragmentation patterns (short to long ratio, 264 dinucleosome fraction) and the burden of mitochondrial cfDNA. We found no significant 265 differences for these metrics (deceased vs. discharged, supplementary figure 3D,E) . 266

We find significant support for the utility of cfDNA profiling as a prognostic tool for the early 268 detection and monitoring of cell and tissue injury associated with COVID-19. An easy to obtain 269 molecular blood test that can inform cell, tissue and organ specific injury due to COVID-19 has 270 the potential to alleviate the impact of the COVID crisis i) by providing quantifiable prognostic 271 parameters and a more granular assessment of clinical severity at the time of presentation; and 272

ii) by providing a surrogate biomarker that can be included in clinical trials of candidate COVID-273 19 treatments. 274

In line with the diverse clinical manifestations of COVID-19, we find evidence for lung, liver and 275 kidney injury in hospitalized patients with COVID-19. While lung-derived cfDNA was elevated in 276 COVID-19 patients, we did not find it to be a major contributor to plasma cfDNA. The level of 277 lung specific cfDNA in plasma was similar to the levels observed in lung transplant patients that 278

suffer acute lung transplant rejection 20 and lung cancer patients 42, 43 . We observed a striking 279 correlation between the total abundance of circulating cfDNA in plasma and the WHO ordinal 280 scale for disease progression. We propose that the total abundance of cfDNA, which can be 281 measured within one hour at a low cost, can be used in the context of clinical trials and patient 282 management in the near term. 283

In addition to the practical application of cfDNA profiling to patient monitoring and COVID-19 risk 284 stratification, the cfDNA methylation assay and data reported may help elucidate aspects of 285 COVID-19 pathogenesis. The most significant cfDNA signature observed in the two cohorts 286 relative to controls was an increase in cfDNA derived from erythroid or red blood progenitor 287 cells. Given that cfDNA is estimated to have a half-life of about 1 hour 44 and that the proportion 288 of the erythroid lineage was relatively stable over several days, the elevated erythroid cfDNA is 289 likely due to an increased erythroid turnover. In support of elevated erythroid turnover and 290 J o u r n a l P r e -p r o o f 8 production, two recent studies have identified red blood cell distribution width (RDW), a 291 measure of the variation in size of red blood cells (RBCs), as an important prognostic predictor 292

for severe COVID-19 15, 16 . The increased RDW is possibly associated with increased turnover of 293

RBCs since increased reticulocytes or newly formed RBCs have a wider diameter 16 Increased erythroid turnover may be due to erythroid destruction as the primary driver, followed 299 by compensatory production, and is supported by anemia (Hgb <13.5 g/dL for men and Hgb < 300 12 for women) found in 26 of 33 COVID-19 patients across both studies. Possible mechanisms 301 include: i) excessive inflammation and cytokine storm 45, 46 , ii) hemophagocytosis in relation to 302 inflammation 47 , and iii) consumption in microthrombi [6] [7] [8] 10 . We note that 18 of 33 patients in all 303 studies, C-reactive protein (CRP) was elevated (> 10 mg/L). It is notable however that 304 megakaryocytes proportions were not increased in either cohort and would not support 305 microthrombi as the predominant reason for increased erythroid turnover. Alternatively, past 306 work has shown that angiotensin II regulates normal erythropoiesis and stimulates early 307 erythroid proliferation through unclear downstream mechanisms [48] [49] [50] . The binding of SARS-308

CoV-2 to the host ACE2 may dysregulate erythropoiesis through the downstream angiotensin II 309

pathway. The significant increase in cfDNA derived from red blood progenitor cells, may 310

alternatively be due to injury to red cell precursors 51 , through direct or indirect processes. 311

These hypotheses are further testable through various routes, including comprehensive 312 evaluation of erythrocytosis in patients with COVID-19, for example through evaluation of 313 circulating reticulocytes and evaluation of the bone marrow; these measures were not 314 systematically in place during the initial rapid wave of the pandemic and were not implemented 315 in this study. 316

In summary, we report the application of cfDNA profiling to quantify cellular and tissue specific 317 injury due to COVID-19. 318

This study has several limitations. First, we assayed samples from only hospitalized patients, 320

and we have not evaluated cfDNA profiles for mild COVID-19 cases. Second, while this study 321 spans two independent cohorts, with patient groups that are genetically and geographically 322 unrelated, the overall sample size and patient numbers may not be sufficient to generalize our 323 findings to the entire spectrum of COVID-19 cases. Nonetheless, our analysis of cfDNA tissues 324 of origin can provide immediate insights into the dynamics and pathogenesis of COVID-19. Last, 325 the resolution of our measurements is limited by the availability of isolated cells and tissue 326 methylation patterns. Our current reference dataset does not include all known human cell types 327 and tissue types. Therefore, we are not sensitive to those rarer tissues that may play a role in 328 the pathogenesis of COVID-19. More comprehensive investigations are therefore needed to 329 confirm and further refine the observations reported here. 330

We thank Dr. Peter Schweitzer and colleagues at the Cornell Genomics Center and the UCSF 332

Center for Advanced Technology for help with sequencing assays. We thank Dr. Lynn Johnson 333 and the Cornell Statistical Consulting Unit for help with statistical analysis. We thank Dr. Lucie sequences were aligned to the human genome (version hg19) and deduplicated using Bismark 477 56 . Alignment files were filtered with a minimum mapping quality of 10 using SAMtools 57 . 478 479

Reference methylomes and tissues of origin 480

Reference methylation profiles were obtained from publicly available datasets and international 481 epigenetic consortium projects (supplementary data 1) and processed as previously described 482 12 25 . Briefly, files were downloaded and normalized to a standard 4 column BED format at single 483 nucleotide resolution using hg19 coordinates. Differentially methylated regions (DMRs) were 484 found using Metilene 58 . Methylation densities within these DMRs were averaged. Tissues with 485 methylation profiles highly dissimilar from the same tissues were removed. cfDNA methylation 486 densities were extracted using Bismark 56 Bisulfite conversion efficiency 500

The bisulfite conversion efficiency achieved in experiments was estimated using MethPipe 59 by 501 calculating the reported methylation density of cytosines present at C[A/T/G] dinucleotides, 502

which are rarely methylated in mammalian genomes. 503 504

Quality control filtering 505

Samples from the high frequency sampling cohort were selected for analysis if 10 or more 506 spike-in molecules were identified after sequencing and were also filtered for sufficient depth of 507 sequencing (>0.2x human genome). Samples from the randomized control trial cohort were 508 sequenced to a minimum depth of 0.7x human genome coverage. All samples had a minimum 509 bisulfite conversion efficiency of 96%. 510 511

Lengths of cfDNA fragments and cfDNA fragmentation patterns to discriminate deceased and 512 recovered COVID-19 patients (MUHC cohort) 513

The lengths of cfDNA molecules were quantified after end-to-end alignment using Bismark 56 . In 514 addition to the mean and median fragment lengths, we investigated i) the ratio of short-to-long 515 molecules described in Cristiano et al. 41 and ii) the fraction of reads attributed to dinucleosome-516 bound cfDNA fragments (approximately 320 bp). For i), we calculated the number of short and 517 long fragments found in consecutive, non-overlapping 100kb bins, after correction for PCR-518

induced GC bias using locally weighted scatterplot smoothing. In each bin, we calculated a 519 fragmentation score defined as the ratio of short to long fragments. The mean for each sample 520 was used to compare recovered COVID-19 patients to the deceased using a non-parametric 521

Wilcoxon test. For ii), we calculated the fraction of reads of lengths greater or equal to 300 bp 522 and shorter or equal to 340 bp and compared the recovered COVID-19 patients to deceased 523 using a non-parametric Wilcoxon test. 524 525

Mitochondrial cfDNA burden 526

The proportion of reads mapped to the mitochondrial genome was multiplied by the cfDNA 527

concentration to obtain the mitochondrial cfDNA burden. 528 529

Multivariate analysis 530

An Extra Trees Classifier was created in Python using the sklearn package (v0. 23 

COVID-19 is a systemic disease with multi-organ involvement. Here, the authors report a blood test to quantify cell, tissue, and organ specific injury due to COVID-19. This is accomplished by profiling methylation marks within circulating cell-free DNA (cfDNA) to trace their tissues-oforigin, and to quantify tissue-specific injury due to COVID-19. The authors assessed the utility of this test to identify subjects with severe disease in two independent, longitudinal cohorts of hospitalized patients and report evidence of injury to the lung and liver and involvement of red blood cell progenitors associated with severe COVID-19. These results support the utility of cfDNA profiling as a prognostic tool for the early detection and monitoring of cell and tissue injury due to COVID-19.

Blood test reported to quantify cell, tissue, and organ specific injury due to COVID-19

Utility of test to identify subjects with severe disease assessed in two patient cohorts Evidence reported of lung and liver injury and involvement of erythroblasts Concentration of cell-free DNA was found to increase with disease progression eTOC BLURB COVID-19 affects the entire body. Cheng et al. describe a DNA-based blood test to quantify cell and tissue injury due to COVID-19. They show that severe COVID-19 is associated with increased lung, liver and erythroblast DNA in blood and that the concentration of cell-free DNA correlates with disease progression. Other respiratory viral infections (n=6) 

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Multiorgan and Renal Tropism of SARS-CoV-2

Extrapulmonary manifestations of COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Severe arterial thrombosis associated with Covid-19 infection

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Mechanisms involved in the development of thrombocytopenia in patients with COVID-19

Leukoerythroblastic reaction in a patient with COVID-19 infection

Elevated RDW is Associated with Increased Mortality Risk in COVID-19. medRxiv

A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China

Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Multisystem Inflammatory Syndrome in Children in New York State

Myriad applications of circulating cell-free DNA in precision organ transplant monitoring

Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood

Noninvasive prenatal diagnosis of fetal chromosomal genomic sequencing of DNA in maternal plasma

Noninvasive monitoring of infection and rejection after lung transplantation

Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection

Universal noninvasive detection of solid organ transplant rejection

Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments

Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin

A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection

Identification of tissue-specific cell death using methylation patterns of circulating DNA

Cell-free DNA Tissues-of-Origin Profiling to Predict Graft versus Host Disease and Detect Infection after Hematopoietic Cell Transplantation. bioRxiv

DNA of erythroid origin is present in human plasma and informs the types of anemia

A minimal common outcome measure set for COVID-19 clinical research

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

An interpretable mortality prediction model for COVID-19 patients

Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease

Early damage indicators in the lung I. Lactate dehydrogenase activity in the airways

Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release

Extremely randomized trees

No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY -RECOVERY Trial

Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

High fragmentation characterizes tumour-derived circulating DNA

Genome-wide cell-free DNA fragmentation in patients with cancer

Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease

Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin

High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing

The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I

Type I interferon-mediated autoinflammation due to DNase II deficiency

Tissue-specific tolerance in fatal Covid-19. medRxiv

Angiotensin II stimulates proliferation of normal early erythroid progenitors

Mechanism of erythropoietin regulation by angiotensin II

The role of the renin-angiotensin system in the regulation of erythropoiesis

COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review

World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects

EDTA Is a Better Anticoagulant than Heparin or Citrate for Delayed Blood Processing for Plasma DNA Analysis

A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands

BBMerge -Accurate paired shotgun read merging via overlap

Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications

The Sequence Alignment/Map format and SAMtools

Fast and sensitive calling of differentially methylated regions from bisulfite sequencing data

A Reference Methylome Database and Analysis Pipeline to Facilitate Integrative and Comparative Epigenomics. El-Maarri O

API design for machine learning software: experiences from the scikit-learn project